Search

Your search keyword '"De Santi L"' showing total 3 results
Start Over Author "De Santi L" Topic cerebrospinal fluid
3 results on '"De Santi L"'

1. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.

Author

Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, Clerici R, Scarpini E, Moscato G, Iudice A, Vacca G, Orefice G, Morra VB, and Maimone D

Subjects
Adult, Biomarkers analysis, Biomarkers cerebrospinal fluid, Central Nervous System drug effects, Central Nervous System pathology, Central Nervous System physiopathology, Disability Evaluation, Disease Progression, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting immunology, Prognosis, Retrospective Studies, Treatment Outcome, Autoantibodies cerebrospinal fluid, Cerebrospinal Fluid immunology, Interferon-beta therapeutic use, Multiple Sclerosis, Relapsing-Remitting cerebrospinal fluid, Multiple Sclerosis, Relapsing-Remitting drug therapy, Oligoclonal Bands cerebrospinal fluid
Abstract

To assess the role of CSF oligoclonal bands (OB) in determining the clinical outcome in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFN-beta, we carried out a retrospective, multicentre, observational study recruiting 209 RRMS patients from six MS centres from northern, central and southern areas of Italy under treatment with IFN-beta-1a i.m., IFN-beta-1a s.c. and IFN-beta-1b s.c. Twenty-two of 209 patients (10.6%) showed no OB in CSF. The patients without had, at disease onset, significantly higher frequency of visual disturbances (p=0.02) and less sensory involvement (p=0.04) than those with OB. A statistical trend (p=0.056) towards a longer time to reach sustained disability progression during treatment was found in patients without compared to those with OB. Thirty-six of 187 (19%) patients with OB worsened by at least 1 EDSS point compared to none of 22 (0%) OB-negative patients (p=0.017). The delaying of disability progression in OB-negative patients during treatment was significantly dependent only on the number of baseline MRI T2-weighted lesions (p=0.012) that was found to be significantly lower in OB-negative than in OB-positive patients (p=0.04). The absence of OB and low number of baseline T2-weighted lesions in this cohort of MS patients are favourable prognostic factors influencing the clinical response to IFN-beta treatment in RRMS patients.

Published
2006
Full Text
View/download PDF

3. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta

Author

Elio Scarpini, Maria Pia Amato, Giuseppe Orefice, G. Vacca, Lorenzo De Santi, Pasquale Annunziata, Davide Maimone, Gianluca Moscato, Raffaella Clerici, Emilio Portaccio, Alfonso Iudice, Antonio Giorgio, Valentina Zipoli, Vincenzo Brescia Morra, Annunziata, P, Giorgio, A, De Santi, L, Zipoli, V, Portaccio, E, Amato, Mp, Clerici, R, Scarpini, E, Moscato, G, Iudice, A, Vacca, G, Orefice, Giuseppe, BRESCIA MORRA, Vincenzo, and Maimone, D.

Subjects
Adult, Central Nervous System, Male, medicine.medical_specialty, multiple sclerosis, oligoclonal IgG bands, Gastroenterology, cerebrospinal fluid, Central nervous system disease, Cerebrospinal fluid oligoclonal bands, Disability Evaluation, Cerebrospinal fluid, Multiple Sclerosis, Relapsing-Remitting, Interferon β, Internal medicine, medicine, Humans, Disability progression, interferon-beta, disability, Autoantibodies, Retrospective Studies, business.industry, Multiple sclerosis, Oligoclonal Bands, Middle Aged, medicine.disease, Prognosis, Magnetic Resonance Imaging, Surgery, Treatment Outcome, Neurology, Relapsing remitting, Cohort, Disease Progression, Female, Neurology (clinical), business, Biomarkers
Abstract

To assess the role of CSF oligoclonal bands (OB) in determining the clinical outcome in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFN-β, we carried out a retrospective, multicentre, observational study recruiting 209 RRMS patients from six MS centres from northern, central and southern areas of Italy under treatment with IFN-β-1a i.m., IFN-β-1a s.c. and IFN-β-1b s.c. Twenty-two of 209 patients (10.6%) showed no OB in CSF. The patients without had, at disease onset, significantly higher frequency of visual disturbances ( p = 0.02) and less sensory involvement ( p = 0.04) than those with OB. A statistical trend ( p = 0.056) towards a longer time to reach sustained disability progression during treatment was found in patients without compared to those with OB. Thirty-six of 187 (19%) patients with OB worsened by at least 1 EDSS point compared to none of 22 (0%) OB-negative patients ( p = 0.017). The delaying of disability progression in OB-negative patients during treatment was significantly dependent only on the number of baseline MRI T2-weighted lesions ( p = 0.012) that was found to be significantly lower in OB-negative than in OB-positive patients ( p = 0.04). The absence of OB and low number of baseline T2-weighted lesions in this cohort of MS patients are favourable prognostic factors influencing the clinical response to IFN-β treatment in RRMS patients.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results